We have located links that may give you full text access.
Journal Article
Review
Cognitive and Neuropsychiatric Features in Parkinson's and Lewy Body Dementias.
Archives of Clinical Neuropsychology : the Official Journal of the National Academy of Neuropsychologists 2017 November 2
Cognitive impairment and neuropsychiatric symptoms affect a substantial number of individuals with Parkinson's disease (PD). These non-motor changes can occur at all stages of disease, often years before motor symptoms manifest in some patients while occurring much later in the disease process for others. Lewy bodies are the hallmark of PD, yet not all patients with PD follow the same course or present in the same way clinically, either from a motor or non-motor standpoint. This has implications on assessment, intervention, and planning for the future. This review will focus on the cognitive and neuropsychiatric features of Parkinson's disease dementia (PDD) and dementia with Lewy bodies (DLB), with emphasis on neuropsychological findings. Differentiation between these dementia syndromes and other atypical parkinsonian syndromes will be mentioned only briefly, as the latter are covered in detail elsewhere in this issue. Neuropathologic, laboratory and radiographic findings will be presented, and recommendations for neurobehavioral assessment and treatment will be provided.
Full text links
Related Resources
Trending Papers
The New Challenge of Obesity - Obesity-Associated Nephropathy.Diabetes, Metabolic Syndrome and Obesity 2024
Advances in Clinical Cardiology 2023: A Summary of Key Clinical Trials.Advances in Therapy 2024 May 15
Oral Anticoagulation Use in Individuals With Atrial Fibrillation and Chronic Kidney Disease: A Review.Seminars in Nephrology 2024 May 15
Nutrition in the intensive care unit: from the acute phase to beyond.Intensive Care Medicine 2024 May 22
Drug Therapy for Acute and Chronic Heart Failure with Preserved Ejection Fraction with Hypertension: A State-of-the-Art Review.American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions 2024 April 5
Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes.Cochrane Database of Systematic Reviews 2024 May 22
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app